Recurrent or metastatic msi-H/DMMR gynecological malignancies

Clinical trials for Recurrent or metastatic msi-H/DMMR gynecological malignancies explained in plain language.

Never miss a new study

Get alerted when new Recurrent or metastatic msi-H/DMMR gynecological malignancies trials appear

Sign up with your email to follow new studies for Recurrent or metastatic msi-H/DMMR gynecological malignancies, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

Can a Two-Drug combo outsmart Hard-to-Treat gynecological cancers?

Disease control Not yet recruiting

This phase II trial is testing whether combining two drugs—sacituzumab tirumotecan and tagitanlimab—can shrink tumors in people with advanced gynecological cancers (ovarian, endometrial, or cervical) that have a specific genetic feature called MSI-H/dMMR. Participants will receiv…

Matched conditions: RECURRENT OR METASTATIC MSI-H/DMMR GYNECOLOGICAL MALIGNANCIES

Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control

Last updated Aug 02, 2026 00:00 UTC

Recurrent or metastatic msi-H/DMMR gynecological malignancies

Get alerted when new Recurrent or metastatic msi-H/DMMR gynecological malignancies trials appear

Can a Two-Drug combo outsmart Hard-to-Treat gynecological cancers?